1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Scinopharm Taiwan, Ltd.

Scinopharm Taiwan, Ltd.

TTWSE:1789
19.45
TWD
-0.15
(-0.77%)
0.07EPS
303.88P/E
16.33BMarket Cap
Nov 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.43
5.18
5
5.1
4.45
4.46
3.66
3.9
3.49
4.13
4.03
4.31
4
3.72
Basic EPS, GAAP
1.61
0.61
0.8
0.83
0.53
0.56
0.27
0.36
0.31
0.45
0.36
0.43
0.17
0.07
Free Cash Flow per Basic Share
-0.39
-0.17
0.48
1.53
0.71
1.4
0.86
0.97
0.24
0.66
-0.07
0.58
0.38
0.7
Dividend per Share
0.99
1.03
0.18
0.28
0.29
0.48
0.49
0.27
0.5
0.48
0.36
0.3
0.35
- -
Book Value per Share
12.2
11.86
12.47
12.93
13.17
13.33
12.98
13.32
13.29
13.22
13.11
13.31
13.31
13.23
Tangible Book Value per Share
12.16
11.83
12.44
12.9
13.14
13.31
12.96
13.3
13.28
13.2
13.08
13.29
13.29
13.21
Basic Weighted Avg Shares
791
791
791
791
791
791
791
791
791
791
791
791
791
831
Sales/Revenue/Turnover
5,088
4,098
3,955
4,031
3,516
3,524
2,893
3,083
2,762
3,264
3,186
3,406
3,163
3,094
Operating Margin (%)
27.47
13.65
18.95
21.54
15.9
15.84
9.23
12.18
10.45
12.43
9.87
9.47
3.44
1.54
Depreciation Expense
448
469
483
445
433
406
409
393
382
439
461
488
517
516
Net Income, GAAP
1,273
484
635
659
422
443
217
282
243
353
287
339
137
56
Effective Tax Rate (%)
9.59
19.61
20.91
18.74
11.14
9.7
18.26
21.32
19.46
19.35
17.71
17.84
7.07
- -
Profit Margin (%)
25.03
11.81
16.05
16.34
12.01
12.57
7.49
9.15
8.81
10.82
9.01
9.96
4.33
1.83
Working Capital
4,369
3,332
3,758
4,894
5,352
4,561
4,665
5,229
5,410
5,517
5,651
5,840
4,781
4,598
LT Debt
- -
- -
- -
771
1,098
- -
590
550
540
581
570
620
609
664
Total Equity
9,643
9,380
9,857
10,228
10,417
10,539
10,260
10,529
10,511
10,450
10,364
10,526
10,525
10,461
Return on Invested Capital (%)
12.64
4.25
5.31
5.93
4.09
4.17
1.9
2.67
2.08
2.92
2.32
2.37
0.9
- -
Return on Capital (%)
13.02
4.64
5.78
5.84
4.07
4.28
2.29
2.66
2.24
3.24
2.66
3.12
1.3
- -
Return on Common Equity (%)
13.61
5.09
6.6
6.56
4.09
4.23
2.08
2.71
2.31
3.37
2.76
3.25
1.3
0.53

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
154
195
209
LT Borrowings
- -
- -
- -
LT Finance Leases
609
667
664
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
791
791
791
Market Capitalization
13,245
16,368
16,329

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,491
5,725
5,827
Cash, Cash Equivalents & STI
3,110
3,265
3,499
Accounts Receivable, Net
612
501
347
Inventories
1,637
1,791
1,820
Total Current Liabilities
710
874
1,229
Payables & Accruals
- -
- -
- -
ST Debt
154
195
209
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.67%
- -
-0.01%
Free Cash Flow
-76.82%
-201.06%
-35.16%
Net Income, GAAP
-7.69%
-5.75%
-59.64%
Sales/Revenue/Turnover
-1.68%
1.03%
-7.13%
Total Cash Common Dividend
13.98%
11.24%
16.67%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
883
762
724
1,036
3,406
2025
686
748
- -
1,008
3,163
2026
660
679
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.09
0.03
0.12
0.43
2025
0.06
0.04
- -
0.05
0.17
2026
0.02
-0.04
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.3
2025
- -
- -
- -
- -
0.35
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Li An Lu
Full Time Employees
1,010
Sector
Health technology
Industry
Biotechnology
Address
No. 1, Nan-Ke 8th Road Tainan TQ Taiwan 741014
IPO Date
Sep 29, 2011
Website
scinopharm.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
ScinoPharm Taiwan, Ltd. (1789.TW) researches, develops, manufactures and sells active pharmaceutical ingredients, injectable drug products and contract development and manufacturing organization services to global pharmaceutical companies. The company offers small molecule APIs, peptide APIs, high potency APIs, protein drugs, complex natural molecules and derivatives, biochemistry molecule synthesis services including peptides and nucleic acids, generic API manufacturing, custom process research and manufacturing, CRAM services encompassing chemistry, analytical, regulatory and consulting support, end-to-end CMC solutions from preclinical to commercial stages, western medicines, chemical materials, albumin and oligonucleotide medicines, and injectable formulations primarily focused on oncology, CNS and cardiovascular therapeutic areas; it operates cGMP facilities with 18 flexible production lines. ScinoPharm Taiwan serves generics and innovative drug makers across Taiwan, rest of Asia including China via subsidiary ScinoPharm Changshu, Europe, the United States, India and emerging markets, with over 950 DMFs filed in more than 100 countries, facilities approved by FDA, EMA, PMDA, TFDA and ANVISA. Founded in 1997 and headquartered in Tainan City, Taiwan, the company pursues a Double-A strategy for global expansion. Recent developments include strategic investment and partnership with Handa Pharmaceuticals to advance 505(b)(2) drug development through shared R&D, clinical trials and commercialization; zero-deficiency US FDA inspections for its injectable plant and China subsidiary in 2024; zero-deficiency ANVISA inspection enhancing emerging market presence; strong H1 2025 financials with NT$1.434 billion revenue amid injectable and CDMO growth; 2024 full-year revenue of NT$3.406 billion up 7% and net profit up 18%; and ongoing expansion into formulation development and CDMO businesses.